Trailing Rivals, AbbVie Scores Win with Dual-Acting Myeloma Drug

An Experimental Myeloma Drug Given Monthly Outperformed Standard Options in Patients Who Exhausted Three Treatment Classes

AbbVie reports that its investigational drug etentamig produced a 74% response rate in relapsed multiple myeloma, against 45.7% for standard therapies.

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

AbbVie's cancer TCE etentamig hits the mark in myeloma

AbbVie has reported positive results with CD3xBCMA bispecific etentamig in multiple myeloma, but can it break into a crowded market?

AbbVie claims Phase 3 win of multiple myeloma drug, seeking to enter crowded market

AbbVie said its T cell engager etentamig cut the risk of disease progression or death by 60% compared with standard therapies in a Phase 3 multiple myeloma trial. The Chicago-area company is now planning to ...